Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.

Yan C, Brunson DC, Tang Q, Do D, Iftimia NA, Moore JC, Hayes MN, Welker AM, Garcia EG, Dubash TD, Hong X, Drapkin BJ, Myers DT, Phat S, Volorio A, Marvin DL, Ligorio M, Dershowitz L, McCarthy KM, Karabacak MN, Fletcher JA, Sgroi DC, Iafrate JA, Maheswaran S, Dyson NJ, Haber DA, Rawls JF, Langenau DM.

Cell. 2019 Jun 13;177(7):1903-1914.e14. doi: 10.1016/j.cell.2019.04.004. Epub 2019 Apr 25.

PMID:
31031007
2.

Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.

Jerevall PL, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ, Wu Y, Erlander MG, Zhang Y, Schnabel CA, Goss PE, Horick N, Sgroi DC.

Breast Cancer Res Treat. 2019 Jan;173(2):375-383. doi: 10.1007/s10549-018-5013-6. Epub 2018 Oct 22.

PMID:
30350269
3.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

4.

A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes.

Zhang Y, Schroeder BE, Jerevall PL, Ly A, Nolan H, Schnabel CA, Sgroi DC.

Clin Cancer Res. 2017 Dec 1;23(23):7217-7224. doi: 10.1158/1078-0432.CCR-17-1688. Epub 2017 Sep 22.

5.

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.

Schroeder B, Zhang Y, Stål O, Fornander T, Brufsky A, Sgroi DC, Schnabel CA.

NPJ Breast Cancer. 2017 Aug 3;3:28. doi: 10.1038/s41523-017-0037-3. eCollection 2017.

6.

Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.

Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S; NISC Comparative Sequencing Program, Lozy F, Sgroi DC, Vidal Bel A, Matias-Guiu X, Broaddus RR, Lu KH, Levine DA, Mutch DG, Goodfellow PJ, Salvesen HB, Mullikin JC, Bell DW.

Cancer. 2017 Sep 1;123(17):3261-3268. doi: 10.1002/cncr.30745. Epub 2017 May 9.

7.

Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions.

Sgroi DC, Brufsky A.

J Clin Oncol. 2016 Nov 10;34(32):3941-3942. doi: 10.1200/JCO.2016.67.2949. No abstract available.

PMID:
27551134
8.

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN.

Breast Cancer Res Treat. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z. Epub 2016 Apr 26.

PMID:
27116182
9.

CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 12-2016. An 8-Year-Old Boy with an Enlarging Mass in the Right Breast.

Misra M, Sagar P, Friedmann AM, Ryan DP, Sgroi DC.

N Engl J Med. 2016 Apr 21;374(16):1565-74. doi: 10.1056/NEJMcpc1503831. No abstract available.

PMID:
27096583
10.

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.

Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M.

Breast Cancer Res. 2016 Jan 4;18(1):1. doi: 10.1186/s13058-015-0660-6.

11.

Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis.

Miyoshi N, Wittner BS, Shioda K, Hitora T, Ito T, Ramaswamy S, Isselbacher KJ, Sgroi DC, Shioda T.

Oncogenesis. 2015 Oct 19;4:e172. doi: 10.1038/oncsis.2015.32.

12.

Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.

Olsen L, Campos B, Winther O, Sgroi DC, Karger BL, Brusic V.

BMC Med Genomics. 2014;7 Suppl 3:S2. doi: 10.1186/1755-8794-7-S3-S2. Epub 2014 Dec 8.

13.

Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.

Rudd ML, Mohamed H, Price JC, O'Hara AJ, Le Gallo M, Urick ME; NISC Comparative Sequencing Program, Cruz P, Zhang S, Hansen NF, Godwin AK, Sgroi DC, Wolfsberg TG, Mullikin JC, Merino MJ, Bell DW.

BMC Cancer. 2014 Nov 26;14:884. doi: 10.1186/1471-2407-14-884.

14.

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.

15.

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.

PMID:
24715381
16.

A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.

Breast Cancer Res. 2014 Mar 14;16(2):R25. doi: 10.1186/bcr3625.

17.

Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS).

Wong JS, Chen YH, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Smith BL, Troyan SL, Harris JR.

Breast Cancer Res Treat. 2014 Jan;143(2):343-50. doi: 10.1007/s10549-013-2813-6. Epub 2013 Dec 18.

PMID:
24346130
18.
19.

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M.

Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

20.

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE.

J Natl Cancer Inst. 2013 Jul 17;105(14):1036-42. doi: 10.1093/jnci/djt146. Epub 2013 Jun 28.

21.

Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A.

Price JC, Pollock LM, Rudd ML, Fogoros SK, Mohamed H, Hanigan CL, Le Gallo M; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Zhang S, Cruz P, Cherukuri PF, Hansen NF, McManus KJ, Godwin AK, Sgroi DC, Mullikin JC, Merino MJ, Hieter P, Bell DW.

PLoS One. 2013 Jun 3;8(6):e63313. doi: 10.1371/journal.pone.0063313. Print 2014.

22.

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

Weiner M, Skoog L, Fornander T, Nordenskjöld B, Sgroi DC, Stål O.

Ann Oncol. 2013 Aug;24(8):1994-9. doi: 10.1093/annonc/mdt159. Epub 2013 May 12.

23.

HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.

Habel LA, Sakoda LC, Achacoso N, Ma XJ, Erlander MG, Sgroi DC, Fehrenbacher L, Greenberg D, Quesenberry CP Jr.

Breast Cancer Res. 2013 Mar 14;15(2):R24. doi: 10.1186/bcr3402.

24.

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Hieter P, Mullikin JC, Merino MJ, Bell DW.

Nat Genet. 2012 Dec;44(12):1310-5. doi: 10.1038/ng.2455. Epub 2012 Oct 28.

25.

Sequence analysis of mutations and translocations across breast cancer subtypes.

Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M.

Nature. 2012 Jun 20;486(7403):405-9. doi: 10.1038/nature11154.

26.

Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse.

Imielinski M, Cha S, Rejtar T, Richardson EA, Karger BL, Sgroi DC.

Mol Cell Proteomics. 2012 Jun;11(6):M111.014910. doi: 10.1074/mcp.M111.014910. Epub 2012 Jan 12.

27.

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML.

J Natl Compr Canc Netw. 2011 Nov;9 Suppl 5:S1-32; quiz S33.

PMID:
22138009
28.

Predisposition to cancer caused by genetic and functional defects of mammalian Atad5.

Bell DW, Sikdar N, Lee KY, Price JC, Chatterjee R, Park HD, Fox J, Ishiai M, Rudd ML, Pollock LM, Fogoros SK, Mohamed H, Hanigan CL; NISC Comparative Sequencing Program, Zhang S, Cruz P, Renaud G, Hansen NF, Cherukuri PF, Borate B, McManus KJ, Stoepel J, Sipahimalani P, Godwin AK, Sgroi DC, Merino MJ, Elliot G, Elkahloun A, Vinson C, Takata M, Mullikin JC, Wolfsberg TG, Hieter P, Lim DS, Myung K.

PLoS Genet. 2011 Aug;7(8):e1002245. doi: 10.1371/journal.pgen.1002245. Epub 2011 Aug 25.

29.

Induction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor library.

Lee J, Hirsh AS, Wittner BS, Maeder ML, Singavarapu R, Lang M, Janarthanan S, McDermott U, Yajnik V, Ramaswamy S, Joung JK, Sgroi DC.

PLoS One. 2011;6(7):e21112. doi: 10.1371/journal.pone.0021112. Epub 2011 Jul 19.

30.

The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.

Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM, Zhu T, Sukumar S.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2736-41. doi: 10.1073/pnas.1018859108. Epub 2011 Jun 20.

31.

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Br J Cancer. 2011 May 24;104(11):1762-9. doi: 10.1038/bjc.2011.145. Epub 2011 May 10.

32.

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.

Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW.

Clin Cancer Res. 2011 Mar 15;17(6):1331-40. doi: 10.1158/1078-0432.CCR-10-0540. Epub 2011 Jan 25.

33.

The molecular pathology of breast cancer progression.

Bombonati A, Sgroi DC.

J Pathol. 2011 Jan;223(2):307-17. doi: 10.1002/path.2808. Epub 2010 Nov 16. Review.

34.

In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology.

Cha S, Imielinski MB, Rejtar T, Richardson EA, Thakur D, Sgroi DC, Karger BL.

Mol Cell Proteomics. 2010 Nov;9(11):2529-44. doi: 10.1074/mcp.M110.000398. Epub 2010 Aug 25.

35.

Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes.

Marselli L, Thorne J, Dahiya S, Sgroi DC, Sharma A, Bonner-Weir S, Marchetti P, Weir GC.

PLoS One. 2010 Jul 13;5(7):e11499. doi: 10.1371/journal.pone.0011499.

36.

The HOXB13:IL17BR gene-expression ratio: a biomarker providing information above and beyond tumor grade.

Sgroi DC.

Biomark Med. 2009 Apr;3(2):99-102. doi: 10.2217/bmm.09.2. No abstract available.

37.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA.

Cancer Res. 2010 Mar 15;70(6):2158-64. doi: 10.1158/0008-5472.CAN-09-3458. Epub 2010 Mar 9.

38.

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE.

J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.

39.

Preinvasive breast cancer.

Sgroi DC.

Annu Rev Pathol. 2010;5:193-221. doi: 10.1146/annurev.pathol.4.110807.092306. Review.

40.

Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin.

Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, Bell DW.

Mol Cancer Res. 2009 Sep;7(9):1510-6. doi: 10.1158/1541-7786.MCR-09-0033. Epub 2009 Sep 8.

41.

Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer.

Burstein HJ, Souter I, D'Alessandro HA, Sgroi DC.

N Engl J Med. 2009 Aug 13;361(7):699-707. doi: 10.1056/NEJMcpc0902224. No abstract available.

PMID:
19675333
42.

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.

Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN.

Mol Cancer Res. 2009 Aug;7(8):1304-9. doi: 10.1158/1541-7786.MCR-09-0149. Epub 2009 Aug 11.

43.

Breast cancer SRC activity: bad to the bone.

Sgroi DC.

Cancer Cell. 2009 Jul 7;16(1):1-2. doi: 10.1016/j.ccr.2009.06.010.

44.

Laser capture microdissection of human pancreatic beta-cells and RNA preparation for gene expression profiling.

Marselli L, Sgroi DC, Bonner-Weir S, Weir GC.

Methods Mol Biol. 2009;560:87-98. doi: 10.1007/978-1-59745-448-3_8.

PMID:
19504246
45.

Gene expression profiling of the tumor microenvironment during breast cancer progression.

Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC.

Breast Cancer Res. 2009;11(1):R7. doi: 10.1186/bcr2222. Epub 2009 Feb 2.

46.

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.

Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN.

Clin Cancer Res. 2008 Sep 15;14(18):5864-8. doi: 10.1158/1078-0432.CCR-08-0619.

47.

Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers.

Hao J, Serohijos AW, Newton G, Tassone G, Wang Z, Sgroi DC, Dokholyan NV, Basilion JP.

PLoS Comput Biol. 2008 Aug 1;4(8):e1000138. doi: 10.1371/journal.pcbi.1000138.

48.

Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification.

Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M, Jiang T, Foley JE, Winfrey RJ, Townsend JA, Unger-Wallace E, Sander JD, Müller-Lerch F, Fu F, Pearlberg J, Göbel C, Dassie JP, Pruett-Miller SM, Porteus MH, Sgroi DC, Iafrate AJ, Dobbs D, McCray PB Jr, Cathomen T, Voytas DF, Joung JK.

Mol Cell. 2008 Jul 25;31(2):294-301. doi: 10.1016/j.molcel.2008.06.016.

49.

Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.

Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, Ramaswamy S.

Clin Cancer Res. 2008 May 15;14(10):2988-93. doi: 10.1158/1078-0432.CCR-07-4723.

50.

Re-evaluating early breast neoplasia.

Moulis S, Sgroi DC.

Breast Cancer Res. 2008;10(1):302. doi: 10.1186/bcr1853. Epub 2008 Feb 8.

Supplemental Content

Loading ...
Support Center